Trial Profile
Therapeutic Approaches to HAART-induced Lipodystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Therapeutic Use
- 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 12 Jun 2012 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.